Get the Stockscreener App
0.7138
3.76%
-0.0279
After Hours:
.70
-0.0138
-1.93%
Abvc Biopharma Inc stock is traded at $0.7138, with a volume of 227.76K.
It is down -3.76% in the last 24 hours and up +36.33% over the past month.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
See More
Previous Close:
$0.7417
Open:
$0.7122
24h Volume:
227.76K
Relative Volume:
0.42
Market Cap:
$16.91M
Revenue:
$152.40K
Net Income/Loss:
$-10.52M
P/E Ratio:
-0.2863
EPS:
-2.4931
Net Cash Flow:
$-4.26M
1W Performance:
+35.70%
1M Performance:
+36.33%
6M Performance:
-0.18%
1Y Performance:
-40.52%
1-Day Range:
$0.681
$0.7407
1-Week Range:
$0.505
$0.82
52-Week Range:
$0.40
$1.73
Abvc Biopharma Inc Stock (ABVC) Company Profile
Name
Abvc Biopharma Inc
Sector
Industry
Phone
510-668-0881
Address
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
0.7138 | 16.91M | 152.40K | -10.52M | -4.26M | -2.4931 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Abvc Biopharma Inc Stock (ABVC) Latest News
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025 - Yahoo Finance
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Decline in Short Interest - Defense World
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 42.6% in December - Defense World
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market - Yahoo Finance
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees - Yahoo Finance
Head to Head Review: ABVC BioPharma (NASDAQ:ABVC) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement - Yahoo Finance
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products - Yahoo Finance
ABVC BioPharma Expands Global Patent Portfolio for ADHD Treatment - Citybuzz
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market - Yahoo Finance
Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Rises By 148.2% - Defense World
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21 - The Manila Times
ABVC BioPharma Seeks to Revolutionize Mental Health - GlobeNewswire
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 24.2% in November - Defense World
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - The Manila Times
ABVC BioPharma Secures $200,000 in First Cash Licensing - GlobeNewswire
ABVC BioPharma Secures Major Oncology Licensing Deal: $200K Initial Payment, Up to $50M in Future Royalties - StockTitan
Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Rises By 79.2% - Defense World
ABVC BioPharma Inc. Reports Operational Profit and Income Growth in Q3 2024 - Defense World
ABVC BioPharma Inc. (ABVC) Quarterly 10-Q Report - Quartzy
ABVCABVC BioPharma, Inc. Latest Stock News & Market Updates - StockTitan
ABVC BioPharma Reports First Operational Profit in Q3 2024, Showcasing Significant Financial Improvement - Citybuzz
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones - The Manila Times
ABVC BioPharma Reports First-Ever Operational Profit, 2,352% Revenue Surge in Q3 | ABVC Stock News - StockTitan
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest - Defense World
ABVC BioPharma Enters into Agreement to Exercise Warrants at Reduced Price - Defense World
ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb - MSN
ABVC BioPharma secures additional licensing fees - Investing.com
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - The Manila Times
ABVC BioPharma secures additional licensing fees By Investing.com - Investing.com UK
ABVC BioPharma switches to new independent accounting firm - Investing.com
ABVC BioPharma switches to new independent accounting firm By Investing.com - Investing.com UK
ABVC BioPharma Inc (ABVC) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
1832 Asset Management L.P. Has $21.08 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Kayne Anderson Rudnick Investment Management LLC Lowers Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Avidity Biosciences initiated with a Buy at Goldman Sachs - TipRanks
ABB unveils number of investors with maximum and minimum stakes in shares - Trend News Agency
ABB (NYSE:ABBNY) Stock Price Passes Above 200 Day Moving Average of $52.74 - MarketBeat
Rhumbline Advisers Sells 495,177 Shares of Ambev S.A. (NYSE:ABEV) - Defense World
Abans Holdings shares: Aditya Birla Money estimates small-cap stock to give multibagger returns. Buy or avoid? | Stock Market News - Mint
ABB (NYSE:ABBNY) Shares Cross Above 200 Day Moving Average of $52.74 - Defense World
Abbott Laboratories (NYSE:ABT) Shares Up 0.3% - MarketBeat
Bank of Montreal Can Trims Stock Holdings in Abbott Laboratories (NYSE:ABT) - Defense World
J. Stern & Co. LLP Has $30.67 Million Position in Abbott Laboratories (NYSE:ABT) - Defense World
Abbott Laboratories (NYSE:ABT) Shares Acquired by Frank Rimerman Advisors LLC - Defense World
ABEV’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Xponance Inc. Has $24.89 Million Position in Abbott Laboratories (NYSE:ABT) - Defense World
Abans Holdings Limited gets buy call with target price of Rs 710 | Check details here - India.com
Abvc Biopharma Inc Stock (ABVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):